C-Reactive Protein: Precise, Penurious and Evidential Diagnostic and Prognostic Biomarker for Oral Squamous Cell Carcinoma: An In vitro study
Context: The number of patients with oral carcinomas is increasing gradually, although the diagnostic modalities and therapeutic management of oral cancer is improving, the treatment outcome and prognosis of oral cancer have improved little. The absence of definite early warning signs for most head and neck cancers suggests that sensitive and specific biomarkers are likely to be important in screening high-risk patients. Aims: To analyse Serum C Reactive Protein levels in Oral Squamous Cell Carcinoma. Settings and Design: A prospective study was performed in Oral squamous cell carcinoma patients who reported our institute. Serum C Reactive Protein levels were analysed. Methods and Material: 90 histopathologically proven cases of Oral squamous cell carcinoma (study group) and 90 normal healthy individuals (control group) selected for study. Statistical analysis used: Independent Sample t-test, One Sample t-test and One-way Analysis of Variance followed by Tuckey’s POST HOC test. Results: Statistically significant increase in serum C Reactive Protein level was observed in Oral Squamous Cell Carcinoma as histopathological grade increased. Conclusion: Serum C Reactive Protein levels in Oral squamous cell carcinoma may be useful diagnostic and prognostic biomarkers in clinical practice and our data warrant a large-scale study to establish and confirm the clinical utility of the same as a prognostic & diagnostic biomarker.
Kerawala CJ. Complications of head and neck cancer surgery: Prevention and management. Oral Oncol. 2010;46:433–5.
Ferlay J, Pisani P, Parkin DM. Globocan. Cancer incidence, mortality and prevalence worldwide. Lyon:IARC Press; 2004.
Lohe VK, Degwekar SS, Bhowate RR, Kadu RP, Dangore SB. Evaluation of correlation of serum lipid profile in patients with oral cancer and precancer and its association with tobacco abuse. J Oral Pathol Med. 2010 Feb;39(2):141-8.
Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006;24(33):5216-22
Dimitrios Trichopoulos, Theodora Psaltopoulou, Philippos Orfanos. Plasma C-Reactive Protein and Risk of Cancer: A Prospective Study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381-84
Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C- reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001;182(2):197-01.
Dr Tim Helliwell, Dr Julia Woolgar. Standards and datasets for reporting cancers Dataset for histopathology reporting of mucosal malignancies of the oral cavity. Royal college of Pathologist. November 2013
Saman Warnakulasuriya. Global epidemiology of oral and pharyngeal cancer. Oral Oncol. 2009;45:309-16.
Coussens LM, Werb Z. Inflammation and Cancer. Nature 2002;420:860-7.
Francesco Colotta, Paola Allavena, Antonio Sica, Cecilia Garlanda and Alberto Mantovani. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis vol.30 no.7 pp.1073–1081, 2009
Allin KH, Bojesen SE, Nordestgaard BG.Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer. J Clin Oncol.2009;27:2217-24.
Chang KP, Kao HK, Wu CC, Fang KH, Chang YL, Huang YC, Liu SC, Cheng MH. Pre-treatment interleukin 6 serum levels are associated with patient’s survival for oral cavity squamous cell carcinoma. Otolaryngol Head Neck Surg.2013;148:786-91
Khandavilli SD, Ceallaigh PQ, Lloyd CJ, Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009;45:912-4.
Jablonska E, Piotrowski L, Grabowska Z.Serum Levels of IL-1β, IL-6, TNF-α, sTNF-RI and CRP in Patients with Oral Cavity. Pathol Oncol Res.1997;3:126-9.
Kim CH, Hwang SY. C-reactive protein changes in oral cancer patients after resection and reconstructive surgery. J Korean Assoc Maxillofac Plast Reconstr Surg. 2010;32:422-30.
Kruse AL, Luebbers HT, Grätz KW. C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head Neck Oncol.2010;2:1-4.
Tariq FA, Janjua OS, Khan U.C-reactive protein as a prognostic indicator of oral squamous cell carcinoma: A retrospective study. Pakistan Oral Dental Journal 2011;31(2):144-7.
Chen HH, Chen IH, Wei FC, Lee LY.Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: A retrospective clinical study. Clin Otolaryngol.2011;36:147–53.
Huang SF, Wei FC, Liao CT, Wang HM, Lin CY, Lo S, Huang JJ, Chen IH, Kang CJ, Chien HT, Chen HH. Risk Stratification in Oral Cavity Squamous Cell Carcinoma by Preoperative CRP and SCC Antigen Levels. Ann Surg Oncol. 2012;19:3856-64.
Gallo O, Gori AM, Attanasio M, Martini F, Giusti B, Brunelli T, et al. Interleukin-6 and acute-phase proteins in head and neck cancer. Eur Arch Otorhinolaryngol 1995;252:159-62.
Vieira FLD, Vieira BJ, Guimaraes MAM, Aarestrup FM. Cellular profile of the peritumoral inflammatory infiltrate insquamous cells carcinoma of oral mucosa: Correlation with theexpression of Ki67 and histologic grading. BMC Oral Health.2008;8:25-9.
Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006;24:5216-22.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 3.0 License.
|Published by Celesta Software Pvt Ltd|